Biotech | August 06, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Subscribe To Our Newsletter & Stay Updated
